Preventing Atrial Fibrillation Related Stroke with Anticoagulants: Selecting Appropriate Therapy for Individual Patients

Curriculum:
Selecting Anticoagulant Therapy for Patients with Atrial Fibrillation
Credits:
1 ACPE 1.16 ANCC Contract Hours 1 AMA PRA Category 1 Credit(s)™
Launch Date:
01-Feb-13
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

No primary audience was provided.

Relevant Terms:

No primary audience was provided.

Elaine Hylek, MD, MPH

Elaine Hylek, MD, MPH
Program Course Director
Professor of Medicine
Boston University School of Medicine
Director, Thrombosis Clinic and Anticoagulation Service    
Boston Medical Center
Boston, Massachusetts 

Elaine M. Hylek, MD, MPH received her MD from the University of Pittsburgh School Of Medicine and a Masters in quantitative methods in Public Health from Harvard University School of Public Health. Dr. Hylek completed her residency training in internal medical at Massachusetts General Hospital and Harvard Medical School in Boston, Massachusetts. While at Massachusetts General Hospital, Dr. Hylek directed the Medical Consultation Service, served as a Director of the Anticoagulation Management Service, and spearheaded a hospital-wide initiative to standardize indication and use of antithrombotic therapy across the surgical and medical services using the American College of Chest Physicians Antithrombotic Guidelines. Most recently, Dr. Hylek participated in the ACCP-convened workgroup on Grading in Developing Clinical Practice Guidelines. Dr. Hylek is currently a clinical investigator, epidemiologist, and Associate Professor of Medicine at Boston University School of Medicine and practicing internist at Boston Medical Center.
 
Dr. Hylek's work has helped to define the therapeutic index of warfarin for stroke prevention in atrial fibrillation, risk factors for intracranial hemorrhage on anticoagulant therapy, the association between acetaminophen and warfarin, and predictors of INR normalization following supratherapeutic levels of anticoagulation. Her research interests also include novel risk factors for thrombus formation in atrial fibrillation, and optimizing the safety of antithrombotic therapy in the geriatric population.
 
Dr. Hylek is on the Editorial Board of Thrombosis Research, and has served as a reviewer for numerous journals including the New England Journal of Medicine, Circulation, JAMA, Annals of Internal Medicine. She serves on the Abstract Grading Panel for the Scientific Sessions Program of the American Heart Association and was among the invited Faculty for the ACCP Consensus Conference on Antithrombotic and Thrombolytic Therapy. Dr. Hylek is a member of the Thrombosis Quorum and several societies, including the American College of Physicians, and the American Heart Association Scientific Councils on Stroke; Arteriosclerosis, Thrombosis, and Vascular Biology; and Epidemiology and Prevention.

Scott Kaatz DO, MSc, FACP

Scott Kaatz DO, MSc, FACP
Chief Quality Officer
Hurley Medical Center
One Hurley Plaza
Flint, Michigan

Scott Kaatz, DO, MSc, FACP is a Clinical Associate Professor of Medicine at Wayne State University.  He attended medical school at Michigan State University and completed his residency in internal medicine at Henry Ford Hospital.  Later in his career, he earned his Master's degree in Evidence-Based Health Care from Oxford University.
 
He has a long standing research interest in anticoagulation and thromboembolic disease and is the Medical Director of the Anticoagulation Clinics for the Henry Ford Health System in Detroit, MI.
 
He considers himself a clinician-educator and serves as an Associate Program Director of Resident Research for the Department of Medicine and maintains an active inpatient and outpatient clinical practice.
 
Dr. Kaatz is a fellow of American College of Physicians, as well as a member of the Society for General Internal Medicine, the Society of Hospital Medicine, the International Society of Thrombosis and Heamostasis and the American Medical Association. He serves on the boards of the National Certification Board of Anticoagulation Providers, AC Forum and the Medical Scientific Advisory Board of the National Blood Clot Alliance.
 
He has participated in many research studies with an emphasis on anticoagulation and venous thromboembolism prevention, diagnosis and treatment; and has published numerous abstracts, articles and book chapter in this field.
1. Describe benefits of oral anticoagulants for stroke prevention in atrial fibrillation 
2. Identify the population of patients who would be at risk of stroke with atrial fibrillation 
3. Compare current and new oral anticoagulants with regards to safety, efficacy, pharmacology, cost and convenience 
4. Compare the benefits and risks of oral anticoagulant therapy for reducing the risk of stroke in atrial fibrillation patients 
5. Utilize available decision making tools to stratify the risks and benefits of anticoagulation therapy in patients with atrial fibrillation 
Boston University Logo